Novel levodopa formulations in the treatment of Parkinson's disease

References

• Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 2002(62):347-76
   PubMedGoogle Scholar
• Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, et al. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord 2008;23(Suppl 3):S548-59
   PubMed Web of Science ®Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56:S1-S88
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-8
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61(7):1044-53
   PubMedGoogle Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342(20):1484-91
   PubMed Web of Science ®Google Scholar
• Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(Suppl 1):23-30
   PubMedGoogle Scholar
• Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2005;21(3):343-53
   Google Scholar
• Parkinson Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009;66(5):563-70
   PubMedGoogle Scholar
• Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001;57(9):1687-94
   PubMed Web of Science ®Google Scholar
• Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22(16):2409-17
   PubMed Web of Science ®Google Scholar
• Rascol O, Korczyn A, De Deyn PP, Lang A. Incidence of dyskinesias in a 10-year naturalistic follow-up of patients with early Parkinson's disease (PD) initially receiving ropinirole compared with L-dopa. Mov Disord 2005;20(Suppl 10):S63
   Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39(11 Suppl 2):7-10
   PubMed Web of Science ®Google Scholar
• Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol 2007;2(3):234-43
   PubMedGoogle Scholar
• Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23(Suppl 3):S580-4
   PubMed Web of Science ®Google Scholar
• Hardie RJ, Lees AJ, Stern GM. Pharmacokinetics of levodopa and motor fluctuations. Adv Neurol 1987;45:487-92
   PubMedGoogle Scholar
• Poewe W, Wenning G. Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E, Parkinson's disease and movement disorders. 4th edition Lippincott Williams and Wilkins; Philadelphia, PA, USAs: 2002
   Google Scholar
• Birkmayer W, Danielcyk W, Neumayer E, Riederer P. L-Dopa level in plasma, primary condition for the kinetic effect. J Neural Transm 1973;34(2):133-43
   PubMedGoogle Scholar
• Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62(6):905-10
   PubMedGoogle Scholar
• Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996;30(6):463-81
   PubMed Web of Science ®Google Scholar
• Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa induced dyskinesias in Parkinson's disease. J Neurol 1999;246:1127-33
   PubMed Web of Science ®Google Scholar
• Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000;247(Suppl 2):II43-50
   Google Scholar
• Calandrella D, Antonini A. Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S120-2
   PubMedGoogle Scholar
• Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trend Neurosci 2000;23(10 Suppl):S117-26
   PubMed Web of Science ®Google Scholar
• Jenner P, McCreary AC, Scheller DK. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 2011;118(12):1691-702
   PubMed Web of Science ®Google Scholar
• Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 2010;24(2):119-29
   PubMed Web of Science ®Google Scholar
• Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(11 Suppl 2):25-38
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Nelson MV, Berchou RC, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(11 Suppl 2):45-53
   PubMed Web of Science ®Google Scholar
• Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol 1987;27(Suppl 1):21-7
   PubMedGoogle Scholar
• Marion MH, Stocchi F, Malcolm SL, et al. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. Eur Neurol 1987;27(Suppl 1):54-8
   PubMedGoogle Scholar
• Stocchi F, Fabbri L, Vecsei L, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007;30(1):18-24
   PubMedGoogle Scholar
• Stocchi F, Zappia M, Dall'Armi V, Melevodopa Plus Carbidopa Study Group. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord 2010;25(12):1881-7
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44(5):913-19
   PubMed Web of Science ®Google Scholar
• Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;29:1233-50
   Google Scholar
• Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005;4:366-70
   PubMed Web of Science ®Google Scholar
• Dingemanse J, Jorga KM, Zurcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62
   PubMed Web of Science ®Google Scholar
• Napolitano A, Del Dotto P, Petrozzi L, et al. Pharmacokinetics and pharmacodynamics of l-dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. Clin Neuropharmacol 1999;22:24-9
   PubMed Web of Science ®Google Scholar
• Limousin P, Pollak P, Pfefen JP, et al. Acute administration of levodopa-beserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;28:358-265
   Google Scholar
• Factor SA, Molho ES, Feustel PJ, et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 2001;24:295-9
   PubMed Web of Science ®Google Scholar
• Szelenyi I, editor. Inhibitors of monoamine oxidase B. Pharmacology and clinical use in neurodegenerative disorders. Birkhäuser Verlag, Basel, Switzerland; 1993
   Google Scholar
• Youdim MB, Riederer PF. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Neurology 2004;63:S32-5
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. a controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-43
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64(2):216-23
   PubMed Web of Science ®Google Scholar
• Mancini F, Comi C, Oggioni GD, et al. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat Disord 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64(5):573-6
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011;258(4):579-85
   PubMed Web of Science ®Google Scholar
• Manca D, Cossu G, Murgia D, et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009;24(15):2293-4
   PubMedGoogle Scholar
• García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008;23(8):1130-6
   PubMed Web of Science ®Google Scholar
• Hardie RJ, Malcolm SL, Lees AJ, et al. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol 1986;22(4):429-36
   PubMedGoogle Scholar
• Juncos JL, Mouradian MM, Fabbrini G, et al. Levodopa methyl ester treatment of Parkinson's disease. Neurology 1987;37(7):1242-5
   PubMedGoogle Scholar
• Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124(Pt 2):331-40
   PubMedGoogle Scholar
• Mao Z, Hsu A, Gupta S, Modi NB. Population Pharmacodynamics of IPX066: an Oral Extended-Release Capsule Formulation of Carbidopa-Levodopa, and Immediate-Release Carbidopa-Levodopa in Patients With Advanced Parkinson's Disease. J Clin Pharmacol 2013;53(5):523
   PubMed Web of Science ®Google Scholar
• Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov Disord 2011;26(12):2246-52
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S, IPX066 ADVANCE-PD investigators. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 2013;12(4):346-56
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Pharmacokinetic and pharmacodynamic profiles of BIA-3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. J Clin Pharmacol 2003;23:1350-2360
   Google Scholar
• Ferreira JJ, Rascol O, Poewe W, BIA-3202-202 Study Investigators. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. CNS Neurosci Ther 2010;16(6):337-47
   PubMedGoogle Scholar
• Jiang C, Wan X, Jankovic J, et al. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol 2004;27(2):63-73
   PubMedGoogle Scholar
• Yang X, Yuan W, Ren T, et al. Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats. Neuroreport 2010;21(12):837-40
   PubMedGoogle Scholar
• Zhou CQ, Li SS, Chen ZM, et al. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. PLoS ONE 2013;8(7):e69738
   PubMedGoogle Scholar
• Babita K, Tiwary AK. Transcutaneous delivery of levodopa: enhancement by fatty acid synthesis inhibition. Mol Pharm 2005;2(1):57-63
   PubMedGoogle Scholar
• Koller W, Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology 2004;62(6 Suppl 4):S22-4
   Google Scholar
• Chun IK, Lee YH, Lee KE, Gwak HS. Design and evaluation of levodopa methyl ester intranasal delivery systems. J Parkinsons Dis 2011;1(1):101-7
   PubMedGoogle Scholar
• Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24(6):826-32
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: www.clinicaltrials.gov-PX066-B09-06
   Google Scholar
• Kelley BJ, Duker AP, Chiu P Dopamine agonists and pathologic behaviors. Parkinsons Dis 2012;2012:603631
   Google Scholar
• Olanow CW, Kieburtz K, Rascol O, Stalevo reduction in dyskinesia evaluation in Parkinson's disease (STRIDE-PD) investigators. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28(8):1064-71
   Google Scholar
• Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996;93(1):14-20
   PubMedGoogle Scholar